Results 31 to 40 of about 125 (92)

Optimal Biologic Drugs for the Treatment of Ankylosing Spondylitis: Results from a Network Meta‐Analysis and Network Metaregression

BioMed Research International, Volume 2022, Issue 1, 2022., 2022
Background. Ankylosing spondylitis (AS) is a common immune‐related systemic chronic inflammatory osteoarthropathy. Previous studies have proven that biologic agents, including IL‐17A inhibitors (IL17Ai), TNF‐α inhibitor FC fusion protein (TNFiFCP), or fully human monoclonal antibody (TNFiNMA) and JAK inhibitor (JAKi), are effective for AS treatment ...
Ziqin Cao, Jia Guo, Qiangxiang Li, Yajia Li, Jianhuang Wu, Nauman Rahim Khan   +5 more
wiley   +1 more source

Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach

Journal of Internal Medicine, Volume 290, Issue 2, Page 257-278, August 2021., 2021
Abstract Psoriasis and inflammatory bowel disease (IBD) are immune‐mediated diseases occurring in barrier organs whose main task is to protect the organism from attack. These disorders are highly prevalent especially in northern Europe where psoriasis has a prevalence of around 3–4% and IBD around 0.3%.
C.R.H. Hedin, E. Sonkoly, M. Eberhardson, M. Ståhle   +3 more
wiley   +1 more source

Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis

Фармакоэкономика, 2021
Objective: to perform cost-effectiveness analysis of the treatment for adult patients with psoriatic arthritis (PsA) with a Russian interleukin- 17А inhibitor netakimab in comparison with other biologic disease-modifying antirheumatic drugs (bDMARDs) and
A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova   +2 more
doaj   +1 more source

Potential for sustaining remission in ankylosing spondylitis patients upon netakimab discontinuation

Meditsinskiy sovet = Medical Council, 2023
Introduction. Biological disease modifying drugs (bDMARD) in the treatment of ankylosing spondylitis (AS) have shown good results with the achievement and long-term preservation of remission. There is a discussion about the withdrawal of drugs without loss of effect in order to reduce the economic burden, drug load, adverse events, the possibility of ...
S. A. Lapshina, A. R. Garaeva, Z. N. Gabdullina, E. V. Sukhorukova, D. I. Abdulganieva   +4 more
openaire   +1 more source

Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?

Современная ревматология, 2021
In recent years, highly effective target drugs – inhibitors of interleukin 17A (iIL17A) – monoclonal antibodies, – have been widely used to treat patients with psoriatic arthritis (PsA).
Т. V. Korotaeva
doaj   +1 more source

Nail psoriasis: dynamics of the clinical course during anti-IL-17 therapy

Медицинский совет, 2022
Psoriasis is a chronic immune-mediated inflammatory disease in which the pathological process quite often involves the nail apparatus. Psoriatic onychodystrophy is considered a serious psychological and social problem, as nail lesions are not only a ...
O. V. Zhukova, S. I. Artemyeva, A.A.-H.M. Al-Hawatmi   +2 more
doaj   +1 more source

Effectiveness of netakimab in real clinical practice in patients with severe forms of psoriasis

Medical alphabet, 2020
Psoriasis refers to genetically deterministic chronic inflammatory dermatoses, which are characterized by systemic immuno-mediated inflammatory response with preferential activation of the IL -23/-17 axis, growth deviation and keratinocyte differentiation.Material and methods.
A. A. Hotko, L. S. Kruglova, M. Yu. Pomazanova, R. A. Hotko   +3 more
openaire   +2 more sources

Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis

Современная ревматология, 2021
Objective: to conduct a cost-effectiveness study of major biologic disease-modifying antirheumatic drugs (bDMARDs) used for the treatment of ankylosing spondylitis (AS) in Russian health care system with the focus on the new effective drug netakimab (NTK)
R. O. Dreval
doaj   +1 more source

POS1043 NETAKIMAB REDUCES PSORIATIC ARTHRITIS ACTIVITY IN PATIENTS WITH OR WITHOUT AXIAL DISEASE: SUBANALYSIS OF THE PATERA STUDY [PDF]

Annals of the Rheumatic Diseases, 2021
Background: PATERA is an ongoing phase 3 international double-blind, placebo-controlled clinical study of netakimab (NTK) in psoriatic arthritis (PsA) (NCT03598751). Netakimab (NTK) is an anti-interleukin-17A monoclonal antibody approved for psoriasis, ankylosing spondylitis, PsA in Russia and Belarus.
T. Korotaeva, I. Gaydukova, V. Mazurov, A. Samtsov, V. Khayrutdinov, A. Bakulev, A. Kundzer, N. Soroka, A. Eremeeva   +8 more
openaire   +1 more source

Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study [PDF]

Vestnik Dermatologii i Venerologii
Background. IL-17 blockers have expanded the possibilities of psoriasis therapy. Their high efficacy and safety profile have been demonstrated in phase I–III studies and in real-world clinical practice.
Arfenya E. Karamova, Anastasiia A. Vorontsova, Olga G. Artamonova   +2 more
doaj   +1 more source